Experienced in Calcium Pyrophosphate Arthritis

Dr. William M. Schnitz

Rheumatology
3555 Nw 58th St, Suite 804, 
Oklahoma City, OK 
Accepting New Patients
Offers Telehealth
Experienced in Calcium Pyrophosphate Arthritis
3555 Nw 58th St, Suite 804, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Schnitz is a Rheumatologist in Oklahoma City, Oklahoma. Dr. Schnitz is rated as an Experienced provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Microscopic Polyangiitis, Necrotizing Vasculitis, and Felty Syndrome. Dr. Schnitz is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in OK
Hospital Affiliations
Onecore Health
Integris Baptist Medical Center, Inc
Stillwater Medical Center
Integris Southwest Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

3555 Nw 58th St, Suite 804, Oklahoma City, OK 73112
Other Locations
CENTRAL OKLAHOMA AMERICAN INDIAN HEALTH COUNCIL, INC.
4913 W Reno Ave, Oklahoma City Indian Clini, Oklahoma City, OK 73127

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Tophaceous gout with rare involvement of the patella.
Tophaceous gout with rare involvement of the patella.
Journal: Radiology case reports
Published: May 29, 2016
Similar Doctors
Advanced in Calcium Pyrophosphate Arthritis
Dr. Zubair Ashraf
Hospital Medicine | Rheumatology
Advanced in Calcium Pyrophosphate Arthritis
Dr. Zubair Ashraf
Hospital Medicine | Rheumatology

Saints Medical Group, LLC

1000 N Lee Ave, Suite 300, 
Oklahoma City, OK 
 (4.9 miles away)
405-272-7000
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Zubair Ashraf is a Hospital Medicine specialist and a Rheumatologist in Oklahoma City, Oklahoma. Dr. Ashraf is rated as an Advanced provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Undifferentiated Connective Tissue Disease (UCTD), Psoriatic Arthritis, and Calcium Pyrophosphate Arthritis. Dr. Ashraf is currently accepting new patients.

Advanced in Calcium Pyrophosphate Arthritis
Dr. Sobia Ahmad
Rheumatology
Advanced in Calcium Pyrophosphate Arthritis
Dr. Sobia Ahmad
Rheumatology

Norman Regional Providers Specialty Care

3300 Healthplex Pkwy, 
Norman, OK 
 (19.5 miles away)
405-515-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sobia Ahmad is a Rheumatologist in Norman, Oklahoma. Dr. Ahmad is rated as a Distinguished provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. Her top areas of expertise are Rheumatoid Arthritis (RA), Sjogren Syndrome, Ankylosing Spondylitis, and Axial Spondyloarthritis (AxSpA). Dr. Ahmad is currently accepting new patients.

Experienced in Calcium Pyrophosphate Arthritis
Dr. Fahed F. Hamadeh
Rheumatology
Experienced in Calcium Pyrophosphate Arthritis
Dr. Fahed F. Hamadeh
Rheumatology

Saints Medical Group, LLC

1000 N Lee Ave, 
Oklahoma City, OK 
 (4.9 miles away)
405-272-7000
Languages Spoken:
English, Arabic, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Fahed Hamadeh is a Rheumatologist in Oklahoma City, Oklahoma. Dr. Hamadeh is rated as a Distinguished provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Microscopic Polyangiitis, Psoriatic Arthritis, Rheumatoid Arthritis (RA), and Psoriasis. Dr. Hamadeh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schnitz's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile